Startup profile · funding coverage
Ollin Bio funding, valuation and investors
Clinical-stage retina biotech advancing OLN324, a VEGF/Ang2 bispecific for DME and wet AMD.
Keep track of Ollin Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$330M · June 24, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$330M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Austin, Texas, USA
Overview
Ollin Biosciences develops biologics for vision-threatening retinal diseases. Lead candidate OLN324 is a VEGF/Ang2 bispecific antibody licensed from China's Innovent Biologics, targeting diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). A Phase 1b study suggested potency and durability advantages vs Roche's Vabysmo per BioPharma Dive. In June 2026 Ollin closed an oversubscribed $330M Series B co-led by ARCH Venture Partners and TCGX, with a16z Bio+Health participating, to fund global Phase 3 trials starting second half 2026. Second program OLN102 targets thyroid eye disease.
Why Ollin Bio is interesting
China-licensed asset beat Roche's Vabysmo in Phase 1b head-to-head — $330M Series B (Jun 2026) from ARCH, TCGX, and a16z Bio+Health funds global Phase 3 starting H2 2026.
Product & use cases
Ollin is clinical-stage, not a platform — it develops injectable biologics for retinal vascular diseases. OLN324 aims to improve on anti-VEGF/Ang2 standards of care with less frequent dosing; OLN102 is a preclinical TSHR/IGF-1R bispecific for thyroid eye disease.
- Treating diabetic macular edema with next-gen anti-VEGF/Ang2 therapy
- Wet AMD patients needing longer-interval injections vs incumbent biologics
- Future thyroid eye disease treatment via OLN102 pipeline
- Global Phase 3 trials including U.S., China, and South Korea via Innovent partnership
Key facts
- Series B (Jun 2026): $330M co-led by ARCH and TCGX; a16z Bio+Health participated — BusinessWire, BioPharma Dive
- Phase 1b suggested OLN324 advantages vs Roche Vabysmo — BioPharma Dive
- Global Phase 3 in DME and wAMD planned H2 2026; FDA End-of-Phase 2 meeting completed
- OLN324 licensed from Innovent Biologics (China partnership model)
- Co-investors not in VCT directory: TCGX, RA Capital, CPP Investments, T. Rowe Price accounts
Funding history (newest first)
Investors in our directory
Funds linked from Ollin Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Head-to-head Phase 1b data vs Vabysmo supports differentiation narrative; Innovent partnership provides China development leverage common in licensed-from-China biotech models.
Retinal injectable biologics are a multi-billion-dollar market dominated by Regeneron and Roche. Ollin's bet is a licensed bispecific can win on dosing interval and efficacy vs Vabysmo. Phase 3 execution and payer uptake determine outcome — $330M Series B signals crossover investor confidence but clinical risk remains high until pivotal readouts.
-
Roche Vabysmo direct
Approved Ang2/VEGF bispecific gaining share from Eylea; Ollin explicitly targets superiority in Phase 3.
-
Regeneron Eylea incumbent
Longtime market leader in retinal anti-VEGF; losing share to bispecifics but entrenched formulary presence.
-
Apellis / other retina entrants adjacent
Multiple companies chase retinal disease with different mechanisms; crowded anti-VEGF class.
Notable stories
- Ollin is part of a wave of U.S. biotechs built on medicines licensed from Chinese developers where Innovent is a frequent partner — BioPharma Dive (Jun 2026).
- The $330M round was among the largest venture biotech financings of 2026, coming immediately after favorable Vabysmo comparison data.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Ollin Bio's financing or category context.
FAQs about Ollin Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.